RCMNY
INDV icon

Rubric Capital Management (New York)’s Indivior Pharmaceuticals INDV Stock Holding History

Rubric Capital Management (New York)’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2M Buy
662,515
+163,988
+33% +$5.42M 0.21% 66
2025
Q4 		$17.9M Sell
498,527
-632,434
-56% -$19.3M 0.21% 58
2025
Q3 		$27.3M Sell
1,130,961
-3,516,218
-76% -$73.6M 0.31% 52
2025
Q2 		$68.5M Buy
4,647,179
+1,117,140
+32% +$13M 1.03% 27
2025
Q1 		$33.6M Buy
3,530,039
+2,170,039
+160% +$22.8M 0.6% 38
2024
Q4 		$16.9M Buy
+1,360,000
New +$14M 0.22% 51

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rubric Capital Management (New York)'s INDV Position: Q1 2026 in Review

Rubric Capital Management (New York) increased its Indivior Pharmaceuticals (INDV) stake by 33% in Q1 2026, buying an estimated $5.42M and bringing the position to 662,515 shares worth $20.2M. The position accounts for 0.21% of the portfolio, ranked #66.

Rubric Capital Management (New York) first reported a position in INDV in Q4 2024 and has held it in 6 quarters since. The position peaked at $68.5M in Q2 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Rubric Capital Management (New York) held 662,515 shares of Indivior Pharmaceuticals worth $20.2M as of Q1 2026.
  • Rubric Capital Management (New York) bought 163,988 Indivior Pharmaceuticals shares in Q1 2026, an estimated $5.42M.
  • Indivior Pharmaceuticals made up 0.21% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #66 holding.
  • Rubric Capital Management (New York) first reported a position in Indivior Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Rubric Capital Management (New York)'s Indivior Pharmaceuticals position peaked at $68.5M in Q2 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.